BlossomHill to present updated Phase 1/2 SOLARA trial data
BlossomHill Therapeutics will present updated Phase 1/2 SOLARA trial data for BH-30643, its macrocyclic OMNI-EGFR inhibitor, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.